Catalyst Pharmaceuticals Inc (STU:CN2)
€ 27.5 (0%) Market Cap: 3.38 Bil Enterprise Value: 2.72 Bil PE Ratio: 18.10 PB Ratio: 3.80 GF Score: 70/100

Catalyst Pharmaceuticals Inc at Barclays Global Healthcare Conference Transcript

Mar 10, 2026 / 07:30PM GMT
Release Date Price: €21.16 (-0.66%)
Glenn Santangelo
Barclays - Analyst

Okay, good afternoon, everyone. Thank you for taking the time to join us here for our next presentation. We're excited to have Catalyst Pharmaceuticals, and joining me from the company to my left is Rich Daly, who's the Chief Executive Officer of the company. For those of you who don't know me, I'm Glenn Santangelo. I'm one of the the life sciences analyst at Barclays. I cover Speck Farm and animal health.

We do not cover Catalyst Pharmaceuticals, but it's been interesting to learn a lot about it in the past several weeks. So really looking forward to the presentation. So thank you, Rich, for joining us. Very glad to have you here.

Rich Daly
Catalyst Pharmaceuticals Inc - President and Chief Executive Officer

Thanks.

Glenn Santangelo
Barclays - Analyst

Maybe a good place for us to. Start for those who don't know the company, maybe we should just spend a minute or two talking about your three primary commercial products or different stages of their life cycle. Maybe

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
7-Day Free Trial · Cancel Anytime
Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot